Ecor1 Capital 13F annual report
Ecor1 Capital is an investment fund managing more than $3.27 trillion ran by Oleg Nodelman. There are currently 52 companies in Mr. Nodelman’s portfolio. The largest investments include Apellis Pharmaceuticals Inc and Prothena Corp Plc, together worth $684 billion.
$3.27 trillion Assets Under Management (AUM)
As of 7th August 2024, Ecor1 Capital’s top holding is 11,607,425 shares of Apellis Pharmaceuticals Inc currently worth over $445 billion and making up 13.6% of the portfolio value.
Relative to the number of outstanding shares of Apellis Pharmaceuticals Inc, Ecor1 Capital owns less than approximately 0.1% of the company.
In addition, the fund holds 11,584,280 shares of Prothena Corp Plc worth $239 billion.
The third-largest holding is Sarepta Therapeutics Inc worth $222 billion and the next is AnaptysBio Inc worth $188 billion, with 7,521,024 shares owned.
Currently, Ecor1 Capital's portfolio is worth at least $3.27 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Ecor1 Capital
The Ecor1 Capital office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Oleg Nodelman serves as the Manager at Ecor1 Capital.
Recent trades
In the most recent 13F filing, Ecor1 Capital revealed that it had opened a new position in
Janux Therapeutics Inc and bought 1,469,818 shares worth $61.6 billion.
The investment fund also strengthened its position in Apellis Pharmaceuticals Inc by buying
250,000 additional shares.
This makes their stake in Apellis Pharmaceuticals Inc total 11,607,425 shares worth $445 billion.
Apellis Pharmaceuticals Inc soared 5.4% in the past year.
On the other hand, there are companies that Ecor1 Capital is getting rid of from its portfolio.
Ecor1 Capital closed its position in Alector on 14th August 2024.
It sold the previously owned 4,056,548 shares for $24.4 billion.
Oleg Nodelman also disclosed a decreased stake in Sarepta Therapeutics Inc by 0.3%.
This leaves the value of the investment at $222 billion and 1,407,322 shares.
One of the largest hedge funds
The two most similar investment funds to Ecor1 Capital are Mutual Advisors and Polar Asset Management Partners. They manage $3.26 trillion and $3.26 trillion respectively.
Oleg Nodelman investment strategy
Ecor1 Capital’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 61.9% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
6% of the total holdings value.
On the other hand, large-cap stocks make up only 1.9% of the portfolio.
The average market cap of the portfolio companies is close to $1.81 billion.
The complete list of Ecor1 Capital trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Apellis Pharmaceuticals Inc |
2.20%
11,607,425
|
$445,260,823,000 | 13.64% |
| Prothena Corp Plc |
No change
11,584,280
|
$239,099,539,000 | 7.32% |
| Sarepta Therapeutics Inc |
26.70%
1,407,322
|
$222,356,876,000 | 6.81% |
| AnaptysBio Inc |
No change
7,521,024
|
$188,476,861,000 | 5.77% |
| Crinetics Pharmaceuticals In |
No change
4,155,375
|
$186,119,246,000 | 5.70% |
| Arvinas Inc |
No change
6,726,491
|
$179,059,190,000 | 5.48% |
| Morphic Hldg Inc |
108.98%
4,982,945
|
$169,768,936,000 | 5.20% |
| Galapagos NV |
No change
5,756,268
|
$142,640,321,000 | 4.37% |
| Kura Oncology Inc |
No change
5,806,871
|
$119,563,474,000 | 3.66% |
| Tango Therapeutics Inc |
No change
13,330,736
|
$114,377,715,000 | 3.50% |
| Zymeworks Inc |
No change
13,437,473
|
$114,352,895,000 | 3.50% |
| Jazz Pharmaceuticals plc |
No change
1,013,952
|
$108,219,097,000 | 3.31% |
| Xencor Inc |
No change
5,330,416
|
$100,904,775,000 | 3.09% |
| CRISPR Therapeutics AG |
No change
1,389,276
|
$75,034,797,000 | 2.30% |
| Janux Therapeutics Inc |
Opened
1,469,818
|
$61,570,676,000 | 1.89% |
| Nuvation Bio Inc |
No change
19,209,643
|
$56,092,158,000 | 1.72% |
| Centessa Pharmaceuticals Plc |
1.70%
5,714,404
|
$51,601,068,000 | 1.58% |
| iTeos Therapeutics, Inc. |
62.55%
3,249,835
|
$48,227,551,000 | 1.48% |
| Immunome, Inc. |
No change
3,879,415
|
$46,940,922,000 | 1.44% |
| Neurogene Inc |
No change
1,271,342
|
$46,264,135,000 | 1.42% |
| Third Harmonic Bio Inc |
No change
3,182,444
|
$41,371,772,000 | 1.27% |
| Mersana Therapeutics Inc |
No change
19,364,688
|
$38,923,023,000 | 1.19% |
| Voyager Therapeutics Inc |
No change
3,917,546
|
$30,987,789,000 | 0.95% |
| Avidity Biosciences, Inc. |
No change
757,576
|
$30,946,980,000 | 0.95% |
| Tscan Therapeutics Inc |
No change
5,000,000
|
$29,250,000,000 | 0.90% |
| Adaptimmune Therapeutics Plc |
No change
27,404,070
|
$26,716,228,000 | 0.82% |
| Alector, Inc. |
Closed
4,056,548
|
$24,420,419,000 | |
| Oric Pharmaceuticals, Inc. |
No change
3,418,068
|
$24,165,741,000 | 0.74% |
| Cargo Therapeutics Inc |
Opened
1,470,000
|
$24,137,400,000 | 0.74% |
| Celldex Therapeutics Inc. |
No change
650,000
|
$24,056,500,000 | 0.74% |
| Vaxcyte, Inc. |
No change
300,000
|
$22,653,000,000 | 0.69% |
| Edgewise Therapeutics Inc |
No change
1,250,385
|
$22,519,434,000 | 0.69% |
| Acadia Pharmaceuticals Inc |
77.53%
1,346,475
|
$21,880,219,000 | 0.67% |
| Nkarta, Inc. |
Closed
2,000,000
|
$21,620,000,000 | |
| Lenz Therapeutics Inc |
No change
1,219,774
|
$21,089,892,000 | 0.65% |
| Madrigal Pharmaceuticals Inc |
No change
75,000
|
$21,012,000,000 | 0.64% |
| Neumora Therapeutics Inc. |
No change
2,071,450
|
$20,362,354,000 | 0.62% |
| Ovid Therapeutics Inc |
Closed
6,117,400
|
$18,658,070,000 | |
| Bicycle Therapeutics plc |
Opened
910,000
|
$18,418,400,000 | 0.56% |
| Atea Pharmaceuticals, Inc. |
11.45%
5,441,896
|
$18,012,676,000 | 0.55% |
| Pharvaris N V |
No change
900,000
|
$16,920,000,000 | 0.52% |
| Dyne Therapeutics, Inc. |
No change
427,039
|
$15,070,206,000 | 0.46% |
| Tectonic Therapeutic Inc |
Opened
849,143
|
$13,985,385,000 | 0.43% |
| Rocket Pharmaceuticals Inc |
Opened
508,393
|
$10,945,701,000 | 0.34% |
| Gossamer Bio, Inc. |
Closed
9,195,404
|
$10,850,577,000 | |
| Keros Therapeutics, Inc. |
No change
187,500
|
$8,568,750,000 | 0.26% |
| Kodiak Sciences Inc |
Closed
1,613,600
|
$8,487,536,000 | |
| AlloVir, Inc. |
No change
11,294,585
|
$8,169,373,000 | 0.25% |
| Replimune Group Inc |
Opened
850,341
|
$7,653,069,000 | 0.23% |
| Atara Biotherapeutics Inc |
Closed
10,167,043
|
$7,055,928,000 | |
| Verve Therapeutics Inc |
No change
1,250,000
|
$6,100,000,000 | 0.19% |
| Generation Bio Co. |
No change
2,046,867
|
$5,772,165,000 | 0.18% |
| Arcutis Biotherapeutics Inc |
Closed
500,000
|
$4,955,000,000 | |
| Prime Medicine Inc |
No change
700,000
|
$3,598,000,000 | 0.11% |
| Atara Biotherapeutics Inc |
Opened
406,679
|
$3,456,772,000 | 0.11% |
| Proqr Thrapeutics N V |
29.18%
2,042,771
|
$3,391,000,000 | 0.10% |
| Hookipa Pharma Inc |
24.42%
5,717,324
|
$3,383,512,000 | 0.10% |
| Kyverna Therapeutics Inc |
No change
450,000
|
$3,375,000,000 | 0.10% |
| Aligos Therapeutics, Inc. |
No change
6,389,468
|
$2,236,314,000 | 0.07% |
| Pmv Pharmaceuticals Inc |
Closed
566,879
|
$963,694,000 | |
| Alpine Immune Sciences Inc |
Closed
1,000
|
$39,640,000 | |
| No transactions found | |||
| Showing first 500 out of 61 holdings | |||
Hedge funds similar to Ecor1 Capital
- Aristotle Capital Boston
- Fort Pitt Capital Group
- Empirical Services, D.b.a. Empirical Wealth Management
- First Horizon Advisors
- Exor N.v
- Capital International Sarl
- Palisade Capital Management, L.P.
- Mutual Advisors
- Polar Asset Management Partners
- Oversea-chinese Banking Corp Ltd
- Facet Wealth
- Kohlberg Kravis Roberts & Co. L.P.
- Apollon Wealth Management
- Par Capital Management Inc